|
1
|
Wu X, Zhang J, Yang S, Kuang Z, Tan G,
Yang G, Wei Q and Guo Z: Telomerase antagonist imetelstat increases
radiation sensitivity in esophageal squamous cell carcinoma.
Oncotarget. 8:13600–13619. 2017.
|
|
2
|
Abnet CC, Arnold M and Wei WQ:
Epidemiology of esophageal squamous cell carcinoma.
Gastroenterology. 154:360–373. 2018.
|
|
3
|
Lin Y, Totsuka Y, Shan B, Wang C, Wei W,
Qiao Y, Kikuchi S, Inoue M, Tanaka H and He Y: Esophageal cancer in
high-risk areas of China: Research progress and challenges. Ann
Epidemiol. 27:215–221. 2017.
|
|
4
|
Zuo J, Wang DH, Zhang YJ, Liu L, Liu FL
and Liu W: Expression and mechanism of PinX1 and telomerase
activity in the carcinogenesis of esophageal epithelial cells.
Oncol Rep. 30:1823–1831. 2013.
|
|
5
|
Domper Arnal MJ, Ferrández Arenas Á and
Lanas Arbeloa Á: Esophageal cancer: Risk factors, screening and
endoscopic treatment in Western and Eastern countries. World J
Gastroenterol. 21:7933–7943. 2015.
|
|
6
|
Zeng H, Zheng R, Zhang S, Zuo T, Xia C,
Zou X and Chen W: Esophageal cancer statistics in China, 2011:
Estimates based on 177 cancer registries. Thorac Cancer. 7:232–237.
2016.
|
|
7
|
Zhu LL, Yuan L, Wang H, Ye L, Yao GY, Liu
C, Sun NN, Li XJ, Zhai SC, Niu LJ, et al: A Meta-analysis of
concurrent chemoradiotherapy for advanced esophageal cancer. PLoS
One. 10:e01286162015.
|
|
8
|
Baker DJ and Petersen RC: Cellular
senescence in brain aging and neurodegenerative diseases: Evidence
and perspectives. J Clin Invest. 128:1208–1216. 2018.
|
|
9
|
Maciejowski J and de Lange T: Telomeres in
cancer: Tumour suppression and genome instability. Nat Rev Mol Cell
Biol. 18:175–186. 2017.
|
|
10
|
Nomikos NN, Nikolaidis PT, Sousa CV,
Papalois AE, Rosemann T and Knechtle B: Exercise, telomeres, and
cancer: ‘The exercise-telomere hypothesis’. Front Physiol.
9:17982018.
|
|
11
|
Jafri MA, Ansari SA, Alqahtani MH and Shay
JW: Roles of telomeres and telomerase in cancer, and advances in
telomerase-targeted therapies. Genome Med. 8:692016.
|
|
12
|
Gunes C, Avila AI and Rudolph KL:
Telomeres in cancer. Differentiation. 99:41–50. 2018.
|
|
13
|
Jaiswal RK, Kumar P, Kumar M and Yadava
PK: hTERT promotes tumor progression by enhancing TSPAN13
expression in osteosarcoma cells. Mol Carcinog. 57:1038–1054.
2018.
|
|
14
|
Aviv A, Anderson JJ and Shay JW:
Mutations, cancer and the telomere length paradox. Trends Cancer.
3:253–258. 2017.
|
|
15
|
Farooqi AA, Mansoor Q, Alaaeddine N and Xu
B: MicroRNA regulation of telomerase reverse transcriptase (TERT):
Micro machines pull strings of papier-mâché puppets. Int J Mol Sci.
19:10512018.
|
|
16
|
Kim NW, Piatyszek MA, Prowse KR, Harley
CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL and Shay
JW: Specific association of human telomerase activity with immortal
cells and cancer. Science. 266:2011–2015. 1994.
|
|
17
|
Alberti L, Losi L, Leyvraz S and Benhattar
J: Different Effects of BORIS/CTCFL on stemness gene expression,
sphere formation and cell survival in epithelial cancer stem cells.
PLoS One. 10:e01329772015.
|
|
18
|
Horikawa I, Cable PL, Afshari C and
Barrett JC: Cloning and characterization of the promoter region of
human telomerase reverse transcriptase gene. Cancer Res.
59:826–830. 1999.
|
|
19
|
Devereux TR, Horikawa I, Anna CH, Annab
LA, Afshari CA and Barrett JC: DNA methylation analysis of the
promoter region of the human telomerase reverse transcriptase
(hTERT) gene. Cancer Res. 59:6087–6090. 1999.
|
|
20
|
Renaud S, Loukinov D, Abdullaev Z,
Guilleret I, Bosman FT, Lobanenkov V and Benhattar J: Dual role of
DNA methylation inside and outside of CTCF-binding regions in the
transcriptional regulation of the telomerase hTERT gene. Nucleic
Acids Res. 35:1245–1256. 2007.
|
|
21
|
Park YJ, Kim EK, Bae JY, Moon S and Kim J:
Human telomerase reverse transcriptase (hTERT) promotes cancer
invasion by modulating cathepsin D via early growth response
(EGR)-1. Cancer Lett. 370:222–231. 2016.
|
|
22
|
Lavanya C, Venkataswamy MM, Sibin MK,
Srinivas Bharath MM and Chetan GK: Down regulation of human
telomerase reverse transcriptase (hTERT) expression by BIBR1532 in
human glioblastoma LN18 cells. Cytotechnology. 70:1143–1154.
2018.
|
|
23
|
Maida Y and Masutomi K: Telomerase reverse
transcriptase moonlights: Therapeutic targets beyond telomerase.
Cancer Sci. 106:1486–1492. 2015.
|
|
24
|
Ding D, Xi P, Zhou J, Wang M and Cong YS:
Human telomerase reverse transcriptase regulates MMP expression
independently of telomerase activity via NF-κB-dependent
transcription. FASEB J. 27:4375–4383. 2013.
|
|
25
|
Jäger K and Walter M: Therapeutic
targeting of telomerase. Genes (Basel). 7:392016.
|
|
26
|
Shi H, Shi D, Wu Y, Shen Q and Li J:
Qigesan inhibits migration and invasion of esophageal cancer cells
via inducing connexin expression and enhancing gap junction
function. Cancer Lett. 380:184–190. 2016.
|
|
27
|
Duff D and Long A: Roles for RACK1 in
cancer cell migration and invasion. Cell Signal. 35:250–255.
2017.
|
|
28
|
Su P, Tian Y, Yang C, Ma X, Wang X, Pei J
and Qian A: Mesenchymal stem cell migration during bone formation
and bone diseases therapy. Int J Mol Sci. 19:23432018.
|
|
29
|
Huang DS, Wang Z, He XJ, Diplas BH, Yang
R, Killela PJ, Meng Q, Ye ZY, Wang W, Jiang XT, et al: Recurrent
TERT promoter mutations identified in a large-scale study of
multiple tumour types are associated with increased TERT expression
and telomerase activation. Eur J Cancer. 51:969–976. 2015.
|
|
30
|
Vinagre J, Almeida A, Pópulo H, Batista R,
Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, et al:
Frequency of TERT promoter mutations in human cancers. Nat Commun.
4:21852013.
|
|
31
|
Kinde I, Munari E, Faraj SF, Hruban RH,
Schoenberg M, Bivalacqua T, Allaf M, Springer S, Wang Y, Diaz LA
Jr, et al: TERT promoter mutations occur early in urothelial
neoplasia and are biomarkers of early disease and disease
recurrence in urine. Cancer Res. 73:7162–7167. 2013.
|
|
32
|
Vail E, Zheng X, Zhou M, Yang X, Fallon
JT, Epstein JI and Zhong M: Telomerase reverse transcriptase
promoter mutations in glandular lesions of the urinary bladder. Ann
Diagn Pathol. 19:301–305. 2015.
|
|
33
|
Pópulo H, Lopes JM, Sobrinho-Simões M and
Soares P: RE: TERT promoter mutation status as an independent
prognostic factor in cutaneous melanoma. J Natl Cancer Inst.
107:djv042015.
|
|
34
|
Horn S, Figl A, Rachakonda PS, Fischer C,
Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, et al:
TERT promoter mutations in familial and sporadic melanoma. Science.
339:959–961. 2013.
|
|
35
|
Qu Y, Shi L, Wang D, Zhang B, Yang Q, Ji
M, Shi B and Hou P: Low frequency of TERT promoter mutations in a
large cohort of gallbladder and gastric cancers. Int J Cancer.
134:2993–2994. 2014.
|
|
36
|
Liu Z, Li Q, Li K, Chen L, Li W, Hou M,
Liu T, Yang J, Lindvall C, Björkholm M, et al: Telomerase reverse
transcriptase promotes epithelial-mesenchymal transition and stem
cell-like traits in cancer cells. Oncogene. 32:4203–4213. 2013.
|
|
37
|
Tang B, Xie R, Qin Y, Xiao YF, Yong X,
Zheng L, Dong H and Yang SM: Human telomerase reverse transcriptase
(hTERT) promotes gastric cancer invasion through cooperating with
c-Myc to upregulate heparanase expression. Oncotarget.
7:11364–11379. 2016.
|
|
38
|
Arita H, Narita Y, Fukushima S, Tateishi
K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP,
Kawahara N, et al: Upregulating mutations in the TERT promoter
commonly occur in adult malignant gliomas and are strongly
associated with total 1p19q loss. Acta Neuropathol. 126:267–276.
2013.
|
|
39
|
Nonoguchi N, Ohta T, Oh JE, Kim YH,
Kleihues P and Ohgaki H: TERT promoter mutations in primary and
secondary glioblastomas. Acta Neuropathol. 126:931–937. 2013.
|
|
40
|
Koelsche C, Sahm F, Capper D, Reuss D,
Sturm D, Jones DT, Kool M, Northcott PA, Wiestler B, Böhmer K, et
al: Distribution of TERT promoter mutations in pediatric and adult
tumors of the nervous system. Acta Neuropathol. 126:907–915.
2013.
|
|
41
|
Killela PJ, Reitman ZJ, Jiao Y, Bettegowda
C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL,
Giovanella BC, et al: TERT promoter mutations occur frequently in
gliomas and a subset of tumors derived from cells with low rates of
self-renewal. Proc Natl Acad Sci USA. 110:6021–6026. 2013.
|
|
42
|
Liu T, Li W, Lu W, Chen M, Luo M, Zhang C,
Li Y, Qin G, Shi D, Xiao B, et al: RBFOX3 promotes tumor growth and
progression via hTERT signaling and predicts a poor prognosis in
hepatocellular carcinoma. Theranostics. 7:3138–3154. 2017.
|
|
43
|
Lu C, Yang L, Chen H and Shan Z:
Upregulated long non-coding RNA BC032469 enhances carcinogenesis
and metastasis of esophageal squamous cell carcinoma through
regulating hTERT expression. Tumour Biol. 37:16065–16075. Oct
10–2016.(Epub ahead of print).
|
|
44
|
Okawa T, Michaylira CZ, Kalabis J, Stairs
DB, Nakagawa H, Andl CD, Johnstone CN, Klein-Szanto AJ, El-Deiry
WS, Cukierman E, et al: The functional interplay between EGFR
overexpression, hTERT activation, and p53 mutation in esophageal
epithelial cells with activation of stromal fibroblasts induces
tumor development, invasion, and differentiation. Genes Dev.
21:2788–2803. 2007.
|
|
45
|
Akincilar SC, Unal B and Tergaonkar V:
Reactivation of telomerase in cancer. Cell Mol Life Sci.
73:1659–1670. 2016.
|
|
46
|
Jaiswal RK, Kumar P, Sharma A, Mishra DK
and Yadava PK: Proteomic identification of proteins differentially
expressed following overexpression of hTERT (human telomerase
reverse transcriptase) in cancer cells. PLoS One.
12:e01810272017.
|
|
47
|
Yang H, Zhang H, Zhong Y, Wang Q, Yang L,
Kang H, Gao X, Yu H, Xie C, Zhou F and Zhou Y: Concomitant
underexpression of TGFBR2 and overexpression of hTERT are
associated with poor prognosis in cervical cancer. Sci Rep.
7:416702017.
|
|
48
|
Kim SH, Cho KH, Kim YN, Jeong BY, Park CG,
Hur GM and Lee HY: Resveratrol attenuates norepinephrine-induced
ovarian cancer invasiveness through downregulating hTERT
expression. Arch Pharm Res. 39:240–248. 2016.
|
|
49
|
Li Z, Liu YH, Diao HY, Ma J and Yao YL:
MiR-661 inhibits glioma cell proliferation, migration and invasion
by targeting hTERT. Biochem Biophys Res Commun. 468:870–876.
2015.
|
|
50
|
Fire A, Xu S, Montgomery MK, Kostas SA,
Driver SE and Mello CC: Potent and specific genetic interference by
double-stranded RNA in Caenorhabditis elegans. Nature. 391:806–811.
1998.
|
|
51
|
Maggisano V, Celano M, Lombardo GE, Lepore
SM, Sponziello M, Rosignolo F, Verrienti A, Baldan F, Puxeddu E,
Durante C, et al: Silencing of hTERT blocks growth and migration of
anaplastic thyroid cancer cells. Mol Cell Endocrinol. 448:34–40.
2017.
|
|
52
|
Chen P, Gu WL, Gong MZ, Wang J and Li DQ:
shRNA-mediated silencing of hTERT suppresses proliferation and
promotes apoptosis in osteosarcoma cells. Cancer Gene Ther.
24:325–332. 2017.
|
|
53
|
da Costa AM, Fregnani JHTG, Pastrez PRA,
Mariano VS, Silva EM, Neto CS, Guimarães DP, Villa LL, Sichero L,
Syrjanen KJ and Longatto-Filho A: HPV infection and p53 and p16
expression in esophageal cancer: Are they prognostic factors?
Infect Agent Cancer. 12:542017.
|
|
54
|
Wang L, Yu X, Li J, Zhang Z, Hou J and Li
F: Prognostic significance of p53 expression in patients with
esophageal cancer: A meta-analysis. BMC Cancer. 16:3732016.
|
|
55
|
Schmidt JC and Cech TR: Human telomerase:
Biogenesis, trafficking, recruitment, and activation. Genes Dev.
29:1095–1105. 2015.
|
|
56
|
Wu X, Smavadati S, Nordfjall K, Karlsson
K, Qvarnström F, Simonsson M, Bergqvist M, Gryaznov S, Ekman S and
Paulsson-Karlsson Y: Telomerase antagonist imetelstat inhibits
esophageal cancer cell growth and increases radiation-induced DNA
breaks. Biochim Biophys Acta. 1823:2130–2135. 2012.
|
|
57
|
Kapoor C, Vaidya S, Wadhwan V, Hitesh;
Kaur G and Pathak A: Seesaw of matrix metalloproteinases (MMPs). J
Cancer Res Ther. 12:28–35. 2016.
|
|
58
|
Guilleret I, Losi L, Chelbi ST, Fonda S,
Bougel S, Saponaro S, Gozzi G, Alberti L, Braunschweig R and
Benhattar J: DNA methylation profiling of esophageal adenocarcinoma
using Methylation Ligation-dependent Macroarray (MLM). Biochem
Biophys Res Commun. 479:231–237. 2016.
|
|
59
|
Clement G, Braunschweig R, Pasquier N,
Bosman FT and Benhattar J: Methylation of APC, TIMP3, and TERT: A
new predictive marker to distinguish Barrett's oesophagus patients
at risk for malignant transformation. J Pathol. 208:100–107.
2006.
|
|
60
|
Wu X, Yan T, Hao L and Zhu Y: Wnt5a
induces ROR1 and ROR2 to activate RhoA in esophageal squamous cell
carcinoma cells. Cancer Manag Res. 11:2803–2815. 2019.
|
